High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1-6 patients without cirrhosis

Puoti, M; Foster, GR; Wang, S; Mutimer, D; Gane, E; Moreno, C; Chang, TT; Lee, SS; Marinho, R; Dufour, JF; Pol, S; Hezode, C; Gordon, SC; Strasser, SI; Thuluvath, PJ; Zhang, ZZ; Lovell, S; Pilot-Matias, T; Mensa, FJ

Puoti, M (reprint author), ASST Grande Osped Metropolitano Niguarda, Dept Infect Dis, Piazza Osped Maggiore 3, I-20162 Milan, Italy.

JOURNAL OF HEPATOLOGY, 2018; 69 (2): 293

Abstract

Background & Aims: Glecaprevir plus pibrentasvir (G/P) is a pangenotypic, once-daily, ribavirin-free direct-acting antiviral (DAA) treatment for h......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索